Examkin

Question

Difficulty: HardGastroenterology and Hepatology

A 58-year-old man is evaluated in the hospital prior to discharge. He was admitted four days ago for right upper quadrant abdominal pain, fever, and malaise. On admission, abdominal ultrasound and computed tomography revealed a 5.5-cm solitary pyogenic liver abscess in the right lobe. A percutaneous drain was placed, and empirical intravenous piperacillin-tazobactam was initiated.

By hospital day 4, the patient's temperature is 37.1°C (98.8°F), blood pressure is 128/78 mmHg, and pulse is 76/min. His leukocyte count has normalized to 7,500/mm³. He is tolerating a regular diet well. The percutaneous drain has had minimal output over the last 24 hours and is removed.

The abscess fluid culture grows *Escherichia coli* and *Bacteroides fragilis*. The antimicrobial susceptibility report shows the following results:

Antimicrobial Agent*Escherichia coli**Bacteroides fragilis*
Amoxicillin-clavulanateResistantNot tested
CeftriaxoneSusceptibleNot tested
CiprofloxacinSusceptibleNot tested
ClindamycinNot testedResistant
MetronidazoleNot testedSusceptible
Piperacillin-tazobactamSusceptibleSusceptible

The patient is being prepared for discharge to complete a 4-week course of antimicrobial therapy. Which of the following is the most appropriate next step in management?

  1. A
    Continue intravenous piperacillin-tazobactam via a peripherally inserted central catheter
  2. B
    Transition to oral amoxicillin-clavulanate
  3. C
    Transition to oral ciprofloxacin
  4. Transition to oral ciprofloxacin and oral metronidazoleAnswer
  5. E
    Transition to intravenous ceftriaxone and oral metronidazole

Answer

Transition to oral ciprofloxacin and oral metronidazole
This patient has a pyogenic liver abscess and has achieved clinical stability after initial drainage and empirical intravenous antibiotics. Because he is afebrile, hemodynamically stable, and tolerating oral intake, he is an excellent candidate for transition to oral therapy. The culture data requires coverage for both the Gram-negative aerobe (*E. coli*) and the anaerobe (*B. fragilis*). Ciprofloxacin provides excellent coverage for the susceptible *E. coli* isolate, and metronidazole provides targeted coverage for the susceptible *B. fragilis* isolate. Both of these medications have excellent oral bioavailability (nearly 100%), allowing for therapeutic tissue concentrations equivalent to IV dosing without the risks associated with a central venous catheter.

Step-by-Step Solution

1
Assess the patient's clinical stability and eligibility for oral therapy.
The patient is afebrile, hemodynamically stable, has a normal leukocyte count, and is tolerating a regular diet.
Stable patients with a functioning gastrointestinal tract should be transitioned from intravenous to oral antibiotics to facilitate discharge and reduce catheter-related risks.
2
Analyze the microbiology culture and susceptibility data.
The infection is polymicrobial, involving a Gram-negative aerobe (Escherichia coli) and an anaerobe (Bacteroides fragilis).
The selected outpatient regimen must provide targeted coverage for all isolated pathogenic organisms.
3
Select the optimal targeted, highly bioavailable oral antimicrobial agents.
Escherichia coli is susceptible to ciprofloxacin, and Bacteroides fragilis is susceptible to metronidazole.
Both ciprofloxacin and metronidazole have nearly 100% oral bioavailability, achieving serum and tissue concentrations comparable to intravenous dosing, making them the ideal outpatient combination.

Key Concept

In patients with pyogenic liver abscess who achieve clinical stability and tolerate oral intake, empirical broad-spectrum intravenous therapy should be de-escalated to a targeted, highly bioavailable oral regimen (e.g., ciprofloxacin and metronidazole) based on culture susceptibilities.
Rate this question

Topics

Gastroenterology and Hepatology

More questions from this topic